{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T22:31:53Z","timestamp":1790980313877,"version":"4.1.0"},"reference-count":305,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["Finance Code 001"],"award-info":[{"award-number":["Finance Code 001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Archiv der Pharmazie"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Neglected tropical diseases are a diverse group of communicable diseases that are endemic in low\u2010 or low\u2010to\u2010middle\u2010income countries located in tropical and subtropical zones. The number and availability of drugs for treating these diseases are low, the administration route is inconvenient in some cases, and most of them have safety, efficacy, or adverse\/toxic reaction issues. The need for developing new drugs to deal with these issues is clear, but one of the most drastic consequences of this negligence is the lack of interest in the research and development of new therapeutic options among major pharmaceutical companies. Positive changes have been achieved over the last few years, although the overall situation remains alarming. After more than one decade since the original work reviewing antiprotozoal agents came to light, now it is time to question ourselves: How has the scenario for the treatment of protozoal diseases such as malaria, leishmaniasis, human African trypanosomiasis, and American trypanosomiasis changed? This review covers the last decade in terms of the drugs currently available for the treatment of these diseases as well as the clinical candidates being currently investigated.<\/jats:p>","DOI":"10.1002\/ardp.202100338","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T08:10:34Z","timestamp":1634803834000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Antiprotozoal agents: How have they changed over a decade?"],"prefix":"10.1002","volume":"355","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2744-9353","authenticated-orcid":false,"given":"Vit\u00f3ria de Souza","family":"Fernandes","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, Pharmaceutical and Medicinal Chemistry Laboratory Federal University of Santa Catarina  Florian\u00f3polis Santa Catarina Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0694-7986","authenticated-orcid":false,"given":"Rafael","family":"da Rosa","sequence":"additional","affiliation":[{"name":"Department of Organic Chemistry, Medicinal Chemistry and Molecular Diversity Laboratory Federal Rural University of Rio de Janeiro  Serop\u00e9dica Rio de Janeiro Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3369-1480","authenticated-orcid":false,"given":"Lara A.","family":"Zimmermann","sequence":"additional","affiliation":[{"name":"Department of Organic Chemistry, Medicinal Chemistry and Molecular Diversity Laboratory Federal Rural University of Rio de Janeiro  Serop\u00e9dica Rio de Janeiro Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0555-9949","authenticated-orcid":false,"given":"Kamilla R.","family":"Rog\u00e9rio","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Pharmaceutical and Medicinal Chemistry Laboratory Federal University of Santa Catarina  Florian\u00f3polis Santa Catarina Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8458-0975","authenticated-orcid":false,"given":"Arthur E.","family":"K\u00fcmmerle","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Pharmaceutical and Medicinal Chemistry Laboratory Federal University of Santa Catarina  Florian\u00f3polis Santa Catarina Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8836-0163","authenticated-orcid":false,"given":"Lilian S. C.","family":"Bernardes","sequence":"additional","affiliation":[{"name":"Department of Organic Chemistry, Medicinal Chemistry and Molecular Diversity Laboratory Federal Rural University of Rio de Janeiro  Serop\u00e9dica Rio de Janeiro Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1410-1227","authenticated-orcid":false,"given":"Cedric S.","family":"Graebin","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Pharmaceutical and Medicinal Chemistry Laboratory Federal University of Santa Catarina  Florian\u00f3polis Santa Catarina Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,10,18]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"WHO Neglected tropical diseases 2021.http:\/\/www.who.int\/neglected_diseases\/diseases\/en\/"},{"key":"e_1_2_9_3_1","first-page":"21","volume":"26","author":"Molyneux D.","year":"2013","journal-title":"Community Eye Health"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0004719"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.4045\/tidsskr.17.0678"},{"key":"e_1_2_9_6_1","unstructured":"WHO \u201cWhy are some tropical diseases called \u2018neglected\u2019? \u201d2021.https:\/\/www.who.int\/westernpacific\/news\/q-a-detail\/why-are-some--diseases-called-neglected"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2018-001334"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0327-4"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph16111925"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2015.11.006"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3156.2010.02629.x"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/bs.apar.2018.02.001"},{"key":"e_1_2_9_13_1","unstructured":"WHO \u201cClimate change and human health\u2014risks and responses. Summary \u201d2021.https:\/\/www.who.int\/globalchange\/climate\/summary\/en\/index5.html"},{"key":"e_1_2_9_14_1","unstructured":"DNDi \u201cBest science for the most neglected \u201d2021.https:\/\/dndi.org\/"},{"key":"e_1_2_9_15_1","unstructured":"Medicines for Malaria Venture \u201cDeveloping antimalarials to save lives \u201d2021.https:\/\/www.mmv.org\/"},{"key":"e_1_2_9_16_1","unstructured":"PATH \u201cBetter health moves humanity forward\u201d 2021.https:\/\/www.path.org\/"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.2174\/187152109789760199"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.13642"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00359-X"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpddr.2016.04.002"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.01.025"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X16683875"},{"key":"e_1_2_9_23_1","unstructured":"NIH Home\u2014ClinicalTrials.gov 2021.https:\/\/clinicaltrials.gov\/"},{"key":"e_1_2_9_24_1","unstructured":"WHO \u201cWorld malaria report \u201d2019.https:\/\/www.who.int\/publications-detail\/world-malaria-report-2019"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-4658.2007.05997.x"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.50"},{"key":"e_1_2_9_27_1","unstructured":"WHO \u201cGHO | By category | Estimated deaths\u2014Estimates by region \u201d2021.https:\/\/apps.who.int\/gho\/data\/view.main.14117?lang=en"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature15535"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1201\/9780203502327"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja01233a516"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/anie.201804551"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja004325r"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1039\/C9SC03879E"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau3174"},{"key":"e_1_2_9_35_1","unstructured":"Centers for Disease Control and Prevention (CDC) \u201cCDC \u2010 Malaria \u2010 Diagnosis & Treatment (United States) \u2010 Treatment (U.S.) \u2010 Guidelines for Clinicians (Part 1) \u201d2020.https:\/\/www.cdc.gov\/malaria\/diagnosis_treatment\/clinicians1.html"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1086\/504873"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.15-0007"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2012.12.007"},{"key":"e_1_2_9_39_1","unstructured":"World Health Organization Guidelines for the Treatment of Malaria World Health Organization Geneva 2015."},{"key":"e_1_2_9_40_1","volume-title":"Pharmacology and Therapeutics: Principles to Practice","author":"Waldman S. A.","year":"2009"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-8-S1-S5"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199243020-00009"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1201\/9781498747967"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199427020-00003"},{"key":"e_1_2_9_45_1","unstructured":"Minist\u00e9rio da Sa\u00fade do Brasil Guia Pr\u00e1tico de Tratamento Da Mal\u00e1ria No Brasil Bras\u00edlia 2010."},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202000895"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1501023112"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0074-02762012000700001"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-019-2724-z"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2011.10507383"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-010-8243-x"},{"key":"e_1_2_9_52_1","volume-title":"Antibiotic and Chemotherapy: Anti\u2010Infective Agents and their Use in Therapy","author":"Finch R. G.","year":"2010"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1177\/0961203318768877"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-11-270"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-7020-5101-2.00088-1"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/0169-4758(91)90267-R"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30291-5"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1201\/b17000-2"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70268-8"},{"key":"e_1_2_9_60_1","volume-title":"Safety of 8\u2010Aminoquinoline Antimalarial Medicines","author":"Recht J.","year":"2014"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001339"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-015-0647-x"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-018-2380-8"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.16.5.705"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11239-0"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.2174\/138161213804070357"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0020-7519(02)00194-7"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm00126a017"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.1586\/eri.09.68"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.08.024"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107697"},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00044-016-1778-5"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trstmh.2007.05.018"},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050295"},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004391"},{"key":"e_1_2_9_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0035-9203(97)90095-X"},{"key":"e_1_2_9_77_1","first-page":"545","volume":"3","author":"Yeates R. A.","year":"2002","journal-title":"Curr. Opin. Invest. Drugs"},{"key":"e_1_2_9_78_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature02779"},{"key":"e_1_2_9_79_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis475"},{"key":"e_1_2_9_80_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-016-1084-1"},{"key":"e_1_2_9_81_1","doi-asserted-by":"publisher","DOI":"10.4103\/2141-9248.139270"},{"key":"e_1_2_9_82_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-015-0982-y"},{"key":"e_1_2_9_83_1","volume-title":"Foye's Principles of Medicinal Chemistry","author":"Foye W. O.","year":"2008"},{"key":"e_1_2_9_84_1","doi-asserted-by":"publisher","DOI":"10.5433\/2316-5200.2013v2n4p59"},{"key":"e_1_2_9_85_1","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taz089"},{"key":"e_1_2_9_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.113084"},{"key":"e_1_2_9_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2005.09.005"},{"key":"e_1_2_9_88_1","doi-asserted-by":"publisher","DOI":"10.1086\/367622"},{"key":"e_1_2_9_89_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10311-013-0404-8"},{"key":"e_1_2_9_90_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-009-0172-6"},{"key":"e_1_2_9_91_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1997.00440340035003"},{"key":"e_1_2_9_92_1","first-page":"431","volume":"30","author":"Riond J. L.","year":"1988","journal-title":"Vet. Hum. Toxicol"},{"key":"e_1_2_9_93_1","doi-asserted-by":"publisher","DOI":"10.4065\/74.8.825"},{"key":"e_1_2_9_94_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.8.2315-2320.2002"},{"key":"e_1_2_9_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-7125(16)30804-5"},{"key":"e_1_2_9_96_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00394-06"},{"key":"e_1_2_9_97_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.9.2395-2398.2000"},{"key":"e_1_2_9_98_1","unstructured":"World Health Organization Global Report on Antimalarial Drug Efficacy and Drug Resistance: 2000\u20132010 2010."},{"key":"e_1_2_9_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(10)70187-0"},{"key":"e_1_2_9_100_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004551"},{"key":"e_1_2_9_101_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku154"},{"key":"e_1_2_9_102_1","first-page":"536","volume":"34","author":"Rojanawatsirivej C.","year":"2003","journal-title":"Southeast Asian J. Trop. Med. Public Health"},{"key":"e_1_2_9_103_1","first-page":"538","volume":"80","author":"Basco L. K.","year":"2002","journal-title":"Bull. W.H.O"},{"key":"e_1_2_9_104_1","unstructured":"WHO Seasonal malaria chemoprevention with sulfadoxine\u2010pyrimethamine plus amodiaquine in children: A field guide 2021.http:\/\/www.who.int\/malaria\/publications\/atoz\/9789241504737\/en\/c"},{"key":"e_1_2_9_105_1","unstructured":"WHO WHO policy recommendation: Seasonal malaria chemoprevention (SMC) forPlasmodium falciparummalaria control in highly seasonal transmission areas of the Sahel sub\u2010region in Africa 2021.https:\/\/www.who.int\/malaria\/publications\/atoz\/who_smc_policy_recommendation\/en"},{"issue":"3","key":"e_1_2_9_106_1","first-page":"353","volume":"66","author":"Huang Q.","year":"1988","journal-title":"Bull. W.H.O"},{"key":"e_1_2_9_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05557-X"},{"key":"e_1_2_9_108_1","first-page":"CD010927","author":"Zani B.","year":"2014","journal-title":"Cochrane Database Syst. Rev"},{"key":"e_1_2_9_109_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-019-2909-5"},{"key":"e_1_2_9_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30378-4"},{"key":"e_1_2_9_111_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-017-1825-9"},{"key":"e_1_2_9_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32321-3"},{"key":"e_1_2_9_113_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2011.11-0160"},{"key":"e_1_2_9_114_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-12-153"},{"key":"e_1_2_9_115_1","doi-asserted-by":"publisher","DOI":"10.1111\/tmi.12352"},{"key":"e_1_2_9_116_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199614040-00001"},{"key":"e_1_2_9_117_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001934"},{"key":"e_1_2_9_118_1","first-page":"123","volume":"9","author":"Kwenti T. E.","year":"2018","journal-title":"Res. Rep. Trop. Med"},{"key":"e_1_2_9_119_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.6b01586"},{"key":"e_1_2_9_120_1","unstructured":"Sanofi A randomized double\u2010blind phase IIb study to investigate the efficacy safety tolerability and pharmacokinetics of a single dose regimen of Ferroquine (FQ) with Artefenomel (OZ439) in adults and children with uncomplicatedPlasmodium falciparummalaria Clinicaltrials.Gov 2020."},{"key":"e_1_2_9_121_1","unstructured":"Medicines for Malaria Venture MMV\u2010supported projects 2021.https:\/\/www.mmv.org\/research-development\/mmv-supported-projects"},{"key":"e_1_2_9_122_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602250"},{"key":"e_1_2_9_123_1","unstructured":"Novartis Pharmaceuticals A phase 2 interventional multicenter randomized open label study to determine the effective and tolerable dose of KAF156 and lumefantrine solid dispersion formulation in combination given once daily for 1 2 and 3\u2010days to adults and children with uncomplicatedPlasmodium falciparummalaria Clinicaltrials.Gov 2021."},{"key":"e_1_2_9_124_1","unstructured":"Novartis Pharmaceuticals A phase 2 interventional multicenter randomized open\u2010label study in three age\u2010descending cohorts to evaluate efficacy safety and tolerability of KAF156 and lumefantrine\u2010SDF combination under fasted or fed conditions in the treatment of acute uncomplicatedPlasmodium falciparummalaria in a pediatric population Clinicaltrials.Gov 2021."},{"key":"e_1_2_9_125_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad9735"},{"key":"e_1_2_9_126_1","unstructured":"Medicines for Malaria Venture First\u2010ever drug compound developed on African soil an antimalarial to move to human trials 2021.https:\/\/www.mmv.org\/newsroom\/news\/first-ever-drug-compound-developed-african-soil-antimalarial-move-human-trials"},{"key":"e_1_2_9_127_1","unstructured":"Medicines for Malaria Venture A proof\u2010of\u2010concept study to assess the effect of MMV390048 against earlyPlasmodium falciparumblood stage infection in healthy participants Clinicaltrials.Gov 2020."},{"key":"e_1_2_9_128_1","unstructured":"Medicines for Malaria Venture An open label study to assess the efficacy safety tolerability and pharmacokinetics of a single dose of MMV390048 in adult patients with acute uncomplicatedPlasmodium vivaxorfalciparummalaria monoinfection over a 35 day period Clinicaltrials.Gov 2020."},{"key":"e_1_2_9_129_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00012-18"},{"key":"e_1_2_9_130_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315860"},{"key":"e_1_2_9_131_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA118.003640"},{"key":"e_1_2_9_132_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2020.101765"},{"key":"e_1_2_9_133_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa6645"},{"key":"e_1_2_9_134_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01837-18"},{"key":"e_1_2_9_135_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30309-8"},{"key":"e_1_2_9_136_1","unstructured":"Medicines for Malaria Venture A proof\u2010of\u2010concept open label study to assess the efficacy safety tolerability and pharmacokinetics of single doses of DSM265 in adult patients with acute uncomplicatedPlasmodium falciparumorvivaxmalaria mono\u2010infection over a 35\u2010day\u2010extended observation period Clinicaltrials.Gov 2016."},{"key":"e_1_2_9_137_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-017-1858-0"},{"key":"e_1_2_9_138_1","doi-asserted-by":"publisher","DOI":"10.1086\/598222"},{"key":"e_1_2_9_139_1","unstructured":"Mahidol University A randomized double\u2010blind placebo\u2010controlled trial of rosiglitazone as adjunctive therapy forP. falciparuminfection Clinicaltrials.Gov 2015."},{"key":"e_1_2_9_140_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.2.735-738.2003"},{"key":"e_1_2_9_141_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)11860-5"},{"key":"e_1_2_9_142_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep00009"},{"key":"e_1_2_9_143_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.16-0332"},{"key":"e_1_2_9_144_1","unstructured":"Jomaa Pharma GmbH Evaluation of fosmidomycin and azithromycin when administered concurrently to adult subjects with acute uncomplicatedPlasmodium salciparummalaria Clinicaltrials.Gov 2011."},{"key":"e_1_2_9_145_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-13-458"},{"key":"e_1_2_9_146_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1045-3"},{"key":"e_1_2_9_147_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu540"},{"key":"e_1_2_9_148_1","doi-asserted-by":"crossref","first-page":"e0222993","DOI":"10.1371\/journal.pone.0222993","volume":"14","author":"Jorge M. M.","year":"2019","journal-title":"PLoS One"},{"key":"e_1_2_9_149_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0911-9"},{"key":"e_1_2_9_150_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30365-1"},{"key":"e_1_2_9_151_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pctr.0020006"},{"key":"e_1_2_9_152_1","doi-asserted-by":"publisher","DOI":"10.1080\/10915810490471352"},{"key":"e_1_2_9_153_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0188754"},{"key":"e_1_2_9_154_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0172718"},{"key":"e_1_2_9_155_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-017-1832-x"},{"key":"e_1_2_9_156_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200767020-00010"},{"key":"e_1_2_9_157_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0031182019000234"},{"key":"e_1_2_9_158_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0164895"},{"key":"e_1_2_9_159_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2015.05.007"},{"key":"e_1_2_9_160_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.20-1165"},{"key":"e_1_2_9_161_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14219"},{"key":"e_1_2_9_162_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02181-19"},{"key":"e_1_2_9_163_1","unstructured":"Merck Healthcare KGaA A phase Ib randomized double\u2010blind placebo controlled sequential study of single oral doses of M5717 to explore the chemoprophylactic activity of M5717 in a controlled PISPZ challenge model in healthy participants Clinicaltrials.Gov 2021."},{"key":"e_1_2_9_164_1","unstructured":"Merck KGaA A phase I first\u2010in\u2010human randomized double\u2010blind placebo\u2010controlled trial of single and multiple ascending doses of M5717 to assess the safety tolerability and pharmacokinetic profile of oral doses and to assess the antimalarial activity of M5717 againstPlasmodium falciparumin healthy male and female adult subjects Clinicaltrials.Gov 2019."},{"key":"e_1_2_9_165_1","unstructured":"J. C.Panetta B. B.Freeman K. R.Guy T. B.Stewart R.Dallas K. C.Branun L.Tang S.Ost N. D.Patel R. N.Heine E.John S.Chalon J. L.Richardson R.Christensen A.Slade P. M.Flynn F.Gusovsky A. H.Gaur J. Pharmacokinet Pharmacodyn.2018 45 3."},{"key":"e_1_2_9_166_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1414221111"},{"key":"e_1_2_9_167_1","unstructured":"R. K.Guy An open oabel phase 2a study to assess the efficacy safety tolerability and pharmacokinetics of (+)\u2010SJ000557733 (SJ733) with or without cobicistat in adult patients with acute uncomplicated malaria over a 42 day period Clinicaltrials.Gov 2021."},{"key":"e_1_2_9_168_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-021-03617-1"},{"key":"e_1_2_9_169_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30611-5"},{"key":"e_1_2_9_170_1","unstructured":"National Institute of Allergy and Infectious Diseases (NIAID) A phase 1 randomized double\u2010blind placebo\u2010controlled trial to evaluate the safety and pharmacokinetics of single and multiple ascending doses and effect of food on the pharmacokinetics of DM1157 in healthy adults Clinicaltrials.Gov 2019."},{"key":"e_1_2_9_171_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01048-15"},{"key":"e_1_2_9_172_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1416611112"},{"key":"e_1_2_9_173_1","doi-asserted-by":"publisher","DOI":"10.1039\/C6CC05277K"},{"key":"e_1_2_9_174_1","unstructured":"GlaxoSmithKline A single\u2010blind placebo\u2010controlled randomized first time in human study to evaluate the safety tolerability and pharmacokinetics of single and repeat dose escalation of GSK932121 in healthy adult subjects Clinicaltrials.Gov 2017."},{"key":"e_1_2_9_175_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-10-63"},{"key":"e_1_2_9_176_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm8012618"},{"key":"e_1_2_9_177_1","doi-asserted-by":"publisher","DOI":"10.1021\/op7002776"},{"key":"e_1_2_9_178_1","doi-asserted-by":"publisher","DOI":"10.15406\/japlr.2017.05.00136"},{"key":"e_1_2_9_179_1","first-page":"115","volume":"42","author":"Parhizgar A. R.","year":"2017","journal-title":"Iran. J. Med. Sci"},{"key":"e_1_2_9_180_1","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.201600298"},{"key":"e_1_2_9_181_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002138"},{"key":"e_1_2_9_182_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04125-14"},{"key":"e_1_2_9_183_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2017.05.042"},{"key":"e_1_2_9_184_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-015-0684-5"},{"key":"e_1_2_9_185_1","doi-asserted-by":"publisher","DOI":"10.1039\/C7MD00637C"},{"key":"e_1_2_9_186_1","first-page":"e372521","volume":"2014","author":"Shafiq N.","year":"2014","journal-title":"Malar. Res. Treat"},{"key":"e_1_2_9_187_1","unstructured":"Medicines for Malaria Venture A randomised open label 2\u2010period crossover study to evaluate the relative bioavailability of atoguanil compared to Malarone\u00ae in healthy adult participants in the fed state Clinicaltrials.Gov 2021."},{"key":"e_1_2_9_188_1","unstructured":"Medicines for Malaria Venture A two\u2010part phase 1 study to assess the safety tolerability and pharmacokinetic profile of ascending single doses of MMV533 Including a pilot food evaluation in healthy participants Clinicaltrials.Gov 2020."},{"key":"e_1_2_9_189_1","unstructured":"WHO Trypanosomiasis human African (sleeping sickness) 2021.https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/trypanosomiasis-human-african-(sleeping-sickness)"},{"key":"e_1_2_9_190_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro848"},{"key":"e_1_2_9_191_1","unstructured":"WHO Cases of sleeping sickness drop to lowest level in 75 years 2021.http:\/\/www.who.int\/trypanosomiasis_african\/news\/cases_drop_to_lowest_since_75_years\/en\/"},{"key":"e_1_2_9_192_1","unstructured":"World Health Organization (WHO) WHO interim guidelines for the treatment of Gambiense human African Trypanosomiasis 2019."},{"key":"e_1_2_9_193_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01168-19"},{"key":"e_1_2_9_194_1","unstructured":"CDC African Trypanosomiasis\u2014resources for health professionals 2020.https:\/\/www.cdc.gov\/parasites\/sleepingsickness\/health_professionals\/index.html"},{"key":"e_1_2_9_195_1","volume-title":"Progress in Human African Trypanosomiasis, Sleeping Sickness","author":"Dumas M.","year":"2013"},{"key":"e_1_2_9_196_1","volume-title":"Harrison's Principles of Internal Medicine 19\/E","author":"Kasper D. L.","year":"2015"},{"key":"e_1_2_9_197_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006980"},{"key":"e_1_2_9_198_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/7.5.625"},{"key":"e_1_2_9_199_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198733030-00002"},{"key":"e_1_2_9_200_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biochi.2008.02.017"},{"key":"e_1_2_9_201_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00642-07"},{"key":"e_1_2_9_202_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(02)00321-3"},{"key":"e_1_2_9_203_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.8.2607"},{"key":"e_1_2_9_204_1","unstructured":"DNDi Nifurtimox\u2010eflornithine combination therapy (NECT) 2003.https:\/\/dndi.org\/research-development\/portfolio\/nect\/"},{"key":"e_1_2_9_205_1","unstructured":"DNDi Prescription of concomitant medications in patients treated with Nifurtimox Eflornithine Combination Therapy (NECT) forT. b. gambiensesecond stage sleeping sickness in the Democratic Republic of the Congo 2020.https:\/\/dndi.org\/scientific-articles\/\/plosntds-prescription-concomitant-medications-patients-treated-nect-second-stage-sleeping-sickness\/"},{"key":"e_1_2_9_206_1","unstructured":"DNDi Nifurtimox\u2010eflornithine combination therapy for second\u2010stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre randomised phase III non\u2010inferiority trial 2009.https:\/\/dndi.org\/scientific-articles\/\/nifurtimox-eflornithine-combination-therapy-for-second-stage-african-trypanosoma-brucei-gambiense-trypanosomiasis\/"},{"key":"e_1_2_9_207_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pt.2014.04.003"},{"key":"e_1_2_9_208_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00332-10"},{"key":"e_1_2_9_209_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/84.18.1432"},{"key":"e_1_2_9_210_1","doi-asserted-by":"publisher","DOI":"10.1086\/432576"},{"key":"e_1_2_9_211_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-3305-3-15"},{"key":"e_1_2_9_212_1","first-page":"1495","volume":"23","author":"Kumar A.","year":"2016","journal-title":"Drug Deliv"},{"key":"e_1_2_9_213_1","unstructured":"DNDi Fexinidazole forT. b. gambiense 2004.https:\/\/dndi.org\/research-development\/portfolio\/fexinidazole\/"},{"key":"e_1_2_9_214_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32758-7"},{"key":"e_1_2_9_215_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-1051-6"},{"key":"e_1_2_9_216_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00246-11"},{"key":"e_1_2_9_217_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000923"},{"key":"e_1_2_9_218_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001151"},{"key":"e_1_2_9_219_1","unstructured":"DNDi Innovative single\u2010dose oral sleeping sickness treatment to be co\u2010developed by Sanofi and DNDi partnership 2020.https:\/\/dndi.org\/press-releases\/\/innovative-single-dose-oral-sleeping-sickness-treatment-to-be-co-developed-by-sanofi-and-dndi\/"},{"key":"e_1_2_9_220_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00498-10"},{"key":"e_1_2_9_221_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1807915115"},{"key":"e_1_2_9_222_1","doi-asserted-by":"publisher","DOI":"10.3390\/tropicalmed5010029"},{"key":"e_1_2_9_223_1","unstructured":"DNDi SCYX\u20101330682 & SCYX\u20101608210 oxaboroles 2006.https:\/\/dndi.org\/research-development\/portfolio\/scyx-1330682\/"},{"key":"e_1_2_9_224_1","unstructured":"OMS 4th WHO NTDs Report\u2014Integrating NTDs into Global Health and Development Geneva 2017."},{"key":"e_1_2_9_225_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.actatropica.2015.06.006"},{"key":"e_1_2_9_226_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.actatropica.2015.05.029"},{"key":"e_1_2_9_227_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.actatropica.2009.11.003"},{"key":"e_1_2_9_228_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0031182012001394"},{"key":"e_1_2_9_229_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60061-X"},{"key":"e_1_2_9_230_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.05.046"},{"key":"e_1_2_9_231_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0004560"},{"key":"e_1_2_9_232_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00537-10"},{"key":"e_1_2_9_233_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507574"},{"key":"e_1_2_9_234_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2010-1172"},{"key":"e_1_2_9_235_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks027"},{"key":"e_1_2_9_236_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx180"},{"key":"e_1_2_9_237_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005794"},{"key":"e_1_2_9_238_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2018.18"},{"key":"e_1_2_9_239_1","doi-asserted-by":"publisher","DOI":"10.1086\/656917"},{"key":"e_1_2_9_240_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.7.1771"},{"key":"e_1_2_9_241_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.1.150-155.2000"},{"key":"e_1_2_9_242_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.12.023"},{"key":"e_1_2_9_243_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(02)00273-X"},{"key":"e_1_2_9_244_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01742-09"},{"key":"e_1_2_9_245_1","first-page":"e00401","volume":"62","author":"de L.","year":"2018","journal-title":"Antimicrob. Agents Chemother"},{"key":"e_1_2_9_246_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30538-8"},{"key":"e_1_2_9_247_1","unstructured":"DNDi New benznidazole regimens 2019.https:\/\/www.dndi.org\/diseases-projects\/portfolio\/new-benz-regimens"},{"key":"e_1_2_9_248_1","unstructured":"DNDi Fexinidazole for Chagas 2019.https:\/\/www.dndi.org\/diseases-projects\/portfolio\/fexinidazole-chagas"},{"key":"e_1_2_9_249_1","unstructured":"Organizaci\u00f3n Panamericana de la Salud Manual de Procedimientos Para La Vigilancia y Control de Las Leishmaniasis En Las Am\u00e9ricas 2019."},{"key":"e_1_2_9_250_1","unstructured":"WHO Releve epidemiologique hebdomadaire 91 2872016."},{"key":"e_1_2_9_251_1","unstructured":"WHO Leishmaniasis\u2014status of endemicity of leishmaniais: 2018 2019."},{"key":"e_1_2_9_252_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006830"},{"key":"e_1_2_9_253_1","unstructured":"World Health Organization (WHO) Control of the Leishmaniasis: report of a Meeting of the WHO Expert Committee on the Control of Leishmaniases Geneva 2010."},{"key":"e_1_2_9_254_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2013.08.005"},{"key":"e_1_2_9_255_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.11120.1"},{"key":"e_1_2_9_256_1","doi-asserted-by":"publisher","DOI":"10.1017\/S003118201600216X"},{"key":"e_1_2_9_257_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00048-18"},{"key":"e_1_2_9_258_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.16-84256"},{"key":"e_1_2_9_259_1","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/9014726"},{"key":"e_1_2_9_260_1","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20153956"},{"key":"e_1_2_9_261_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0035-9203(00)90130-5"},{"key":"e_1_2_9_262_1","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(90)90263-E"},{"key":"e_1_2_9_263_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62050-8"},{"key":"e_1_2_9_264_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005706"},{"key":"e_1_2_9_265_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0007726"},{"key":"e_1_2_9_266_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000855"},{"key":"e_1_2_9_267_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001674"},{"key":"e_1_2_9_268_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005635"},{"key":"e_1_2_9_269_1","unstructured":"C. T. D Register India Clinical trial details 2016."},{"key":"e_1_2_9_270_1","unstructured":"ClinicalTrials.gov Miltefosine\/paromomycin phase iii trial for treatment of primary visceral leishmaniasis (VL) patients in Eastern Africa 2021."},{"key":"e_1_2_9_271_1","unstructured":"A.Ababa Report of the fifth consultative meeting on leishmania\/HIV coinfection 2021."},{"key":"e_1_2_9_272_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002613"},{"key":"e_1_2_9_273_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir674"},{"key":"e_1_2_9_274_1","first-page":"14","volume":"8","author":"Diro E.","year":"2014","journal-title":"PLoS Neglected Trop. Dis"},{"key":"e_1_2_9_275_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006988"},{"key":"e_1_2_9_276_1","unstructured":"DNDi New treatments for PKDL 2019."},{"key":"e_1_2_9_277_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy891"},{"key":"e_1_2_9_278_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx283"},{"key":"e_1_2_9_279_1","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-12-166"},{"key":"e_1_2_9_280_1","first-page":"1530","volume":"68","author":"Mbui J.","year":"2018","journal-title":"Clin. Infect. Dis"},{"key":"e_1_2_9_281_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006653"},{"key":"e_1_2_9_282_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0122569"},{"key":"e_1_2_9_283_1","unstructured":"ClinicalTrials.gov Thermotherapy\u2009+\u2009a short course of miltefosine for the treatment of uncomplicated cutaneous leishmaniasis in the new world 2021."},{"key":"e_1_2_9_284_1","unstructured":"DNDi Fexinidazole\/Miltefosine Combination (VL) 2021."},{"key":"e_1_2_9_285_1","doi-asserted-by":"publisher","DOI":"10.1093\/milmed\/usaa468"},{"key":"e_1_2_9_286_1","doi-asserted-by":"publisher","DOI":"10.1051\/parasite\/2011182115"},{"key":"e_1_2_9_287_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2011.10-0409"},{"key":"e_1_2_9_288_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2005.73.871"},{"key":"e_1_2_9_289_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2003.01955.x"},{"key":"e_1_2_9_290_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000491"},{"key":"e_1_2_9_291_1","unstructured":"ClinicalTrials.gov Oral miltefosine plus topical imiquimod to treat cutaneous leishmaniasis 2021."},{"key":"e_1_2_9_292_1","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/3062892"},{"key":"e_1_2_9_293_1","unstructured":"ClinicalTrials.gov Fourth\u2010generation immucillin derivative DI4G associated therapy in cutaneous leishmaniasis 2021."},{"key":"e_1_2_9_294_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpddr.2019.02.002"},{"key":"e_1_2_9_295_1","unstructured":"DNDi 2019 R&D portfolio in review: Leishmaniasis 2020."},{"key":"e_1_2_9_296_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b00034"},{"key":"e_1_2_9_297_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005971"},{"key":"e_1_2_9_298_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00829-19"},{"key":"e_1_2_9_299_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b01218"},{"key":"e_1_2_9_300_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0356-z"},{"key":"e_1_2_9_301_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1820175116"},{"key":"e_1_2_9_302_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0008050"},{"key":"e_1_2_9_303_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c00499"},{"key":"e_1_2_9_304_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2003.09.002"},{"key":"e_1_2_9_305_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2016.03.103"},{"key":"e_1_2_9_306_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2018.168"}],"container-title":["Archiv der Pharmazie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ardp.202100338","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ardp.202100338","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ardp.202100338","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T13:17:56Z","timestamp":1692537476000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ardp.202100338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,18]]},"references-count":305,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1002\/ardp.202100338"],"URL":"https:\/\/doi.org\/10.1002\/ardp.202100338","archive":["Portico"],"relation":{},"ISSN":["0365-6233","1521-4184"],"issn-type":[{"value":"0365-6233","type":"print"},{"value":"1521-4184","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,18]]},"assertion":[{"value":"2021-09-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2100338"}}